Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $196,277.41 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Alfred Ford, Jr. sold 8,681 shares of the stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $22.61, for a total transaction of $196,277.41. Following the transaction, the insider owned 118,854 shares in the company, valued at approximately $2,687,288.94. The trade was a 6.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Price Performance

KMTS opened at $25.06 on Thursday. Kestra Medical Technologies, Ltd. has a 1 year low of $14.10 and a 1 year high of $30.00. The company’s 50 day simple moving average is $22.78 and its 200 day simple moving average is $22.52. The stock has a market capitalization of $1.47 billion, a PE ratio of -10.36 and a beta of 0.58. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The company had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. As a group, sell-side analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Wall Street Analyst Weigh In

KMTS has been the topic of several research reports. Wall Street Zen lowered Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. The Goldman Sachs Group dropped their price target on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. Oppenheimer assumed coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating on the stock. Finally, BTIG Research boosted their target price on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Kestra Medical Technologies has a consensus rating of “Hold” and a consensus target price of $27.83.

Institutional Investors Weigh In On Kestra Medical Technologies

Hedge funds have recently modified their holdings of the stock. Seven Grand Managers LLC acquired a new position in Kestra Medical Technologies during the 4th quarter worth approximately $2,652,000. Eventide Asset Management LLC grew its position in Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after acquiring an additional 65,288 shares in the last quarter. Summit Partners Public Asset Management LLC purchased a new stake in shares of Kestra Medical Technologies during the fourth quarter valued at approximately $9,282,000. UBS Group AG raised its stake in shares of Kestra Medical Technologies by 34.9% during the fourth quarter. UBS Group AG now owns 270,058 shares of the company’s stock valued at $7,162,000 after purchasing an additional 69,908 shares during the period. Finally, Jennison Associates LLC lifted its position in shares of Kestra Medical Technologies by 15.0% during the fourth quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock worth $5,817,000 after purchasing an additional 28,573 shares in the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.